JLE

Epileptic Disorders

MENU

Effect of long-term valproic acid therapy on lipid profiles in paediatric patients with epilepsy: a meta-analysis Volume 24, numéro 5, October 2022

Illustrations


  • Figure 1.

  • Figure 2.

  • Figure 3.

  • Figure 4.

  • Figure 5.

Tableaux

Auteurs
1 Pharmaceutical Sciences Research Center, Department of Pharmacy, Children’s Hospital of Nanjing Medical University, China
2 Institute of Pharmaceutical Sciences, China Pharmaceutical University, China
3 Department of Pneumology, Children’s Hospital of Nanjing Medical University, China
4 Department of Neurology, Children’s Hospital of Nanjing Medical University, China
* Authors contributed equally
Correspondence:
Man Tian
Jin-Chun Qiu
Children’s Hospital of Nanjing Medical University, 72 Guangzhou Road, Nanjing 210008, China

Objective

Despite the potential role of valproic acid (VPA) in weight gain, the effects of VPA therapy on lipid profiles remain unclear. This study aimed to review the influence of VPA therapy on serum lipid profiles in children with epilepsy.

Methods

This meta-analysis was conducted on data from PubMed, Web of Science, Cochrane Library, and Embase databases. Case-controlled studies, which assessed the effects of VPA therapy on lipid profiles, were included. All outcomes were recorded as continuous variables, and the effect size was measured.

Results

VPA therapy was associated with a significant reduction in total cholesterol (mean difference [MD]=-6.34, 95% confidence interval [CI]: -12.30, -0.37, p=0.04) and low-density lipoprotein cholesterol levels (MD = -7.75, 95% CI: -13.48, -2.0, p=0.008). No significant effects were observed regarding the levels of high-density lipoprotein cholesterol and triglycerides.

Significance

In conclusion, this meta-analysis indicates that VPA therapy causes a decrease in the levels of total cholesterol and low-density lipoprotein cholesterol.